Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/44597
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | The use of anti-mullerian hormone in predicting menstrual response after weight loss in overweight women with polycystic ovary syndrome |
Author: | Moran, L. Noakes, M. Clifton, P. Norman, R. |
Citation: | Journal of Clinical Endocrinology and Metabolism, 2007; 92(10):3796-3802 |
Publisher: | Endocrine Society |
Issue Date: | 2007 |
ISSN: | 0021-972X 0021-972X |
Statement of Responsibility: | Lisa J. Moran, Manny Noakes, Peter M. Clifton and Robert J. Norman |
Abstract: | <h4>Background</h4>Polycystic ovary syndrome (PCOS) is associated with reproductive and metabolic abnormalities, specifically menstrual dysfunction and anovulation in conjunction with elevated pre-antral follicle number and arrested follicular maturation. Although anti-müllerian hormone (AMH), an inhibitor of follicle recruitment and maturation, is increased in women with PCOS, the usefulness of circulating AMH levels as a clinical predictor of menstrual response to weight loss in PCOS is not known.<h4>Methods</h4>Overweight women with PCOS (n = 26, age 32.9 +/- 5.8 yr, weight 98.9 +/- 20.8 kg, body mass index 36.1 +/- 7.0 kg/m(2), mean +/- sd) followed an 8-wk weight loss and 6-month weight maintenance program.<h4>Results</h4>Net reductions in weight (4.6 +/- 4.8 kg), waist circumference (6.0 +/- 5.3 cm), testosterone (0.3 +/- 0.6 nmol/liter), fasting insulin (3.7 +/- 7.6 mU/liter), and the homeostasis model assessment of insulin sensitivity (0.7 +/- 1.3) occurred for all subjects over the entire study duration. Of 26 subjects, 15 (57.7%) responded to the intervention with improvements in menstrual cyclicity (responders). Compared to nonresponders, responders had lower AMH levels at baseline (23.6 +/- 12.0 vs. 37.9 +/- 17.8 pmol/liter; P = 0.021). Only responders had reductions in fasting insulin (6.1 +/- 5.9 mU/liter; P = 0.001) and homeostasis model assessment (1.3 +/- 5.9; P = 0.002) with acute weight loss (wk 0-8). Baseline AMH was most strongly predicted by baseline ghrelin, free testosterone, and insulin (r(2) = 0.528; P = 0.002).<h4>Conclusions</h4>Overweight women with PCOS who respond to weight loss with menstrual improvements have significantly reduced preweight loss AMH and demonstrate improvements in surrogate measures of insulin resistance with weight loss. Pretreatment AMH is a potential clinical predictor of menstrual improvements with weight loss in PCOS. |
Keywords: | Humans Polycystic Ovary Syndrome Weight Loss Gonadal Steroid Hormones Insulin Blood Glucose Lipids C-Reactive Protein Body Mass Index Regression Analysis Predictive Value of Tests Body Composition Energy Intake Homeostasis Menstrual Cycle Adult Female Overweight Anti-Mullerian Hormone Biomarkers |
Description: | Copyright © 2007 by The Endocrine Society |
DOI: | 10.1210/jc.2007-1188 |
Published version: | http://jcem.endojournals.org/cgi/reprint/92/10/3796 |
Appears in Collections: | Aurora harvest 6 Obstetrics and Gynaecology publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.